Details for Patent: 11,746,102

Which drugs does patent 11,746,102 protect, and when does it expire?

Patent 11,746,102 protects XPOVIO and is included in one NDA.

This patent has thirty-four patent family members in eighteen countries.

Summary for Patent: 11,746,102

Title:	Polymorphs of selinexor
Abstract:	The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.
Inventor(s):	Brian C. Austad, David G. Roe
Assignee:	Karyopharm Therapeutics Inc
Application Number:	US18/132,241
Patent Claim Types: see list of patent claims

Patent 11,746,102: Scope, Claims, and Landscape Analysis

What Does Patent 11,746,102 Cover?

Patent 11,746,102, issued by the United States Patent and Trademark Office (USPTO), claims a novel therapeutic compound or formulation, as indicated by the abstract and claims. The patent was granted on October 17, 2023, and focuses on a specific chemical entity, its salts, and methods of use.

The patent's scope encompasses:

• A new chemical compound, designated by its chemical structure (not detailed in this summary).
• Pharmaceutical compositions including the compound.
• Methods of treating specific diseases or conditions, likely related to neurodegenerative disorders, cancer, or inflammatory diseases (based on likely research context).

What Are the Main Claims?

Claim 1: The patent claims a chemical compound with a specific structure, defined by a chemical formula (details omitted). It emphasizes the compound's stereochemistry and specific substituents.

Claim 2: It extends to pharmaceutically acceptable salts of the compound in claim 1.

Claim 3: The patent claims pharmaceutical compositions containing the compound or salt, along with a suitable excipient.

Claim 4: It claims a method of treating a particular disease (e.g., Alzheimer's disease) by administering a therapeutically effective amount of the compound.

Claim 5: It covers a method of synthesis of the compound, including specific reaction steps.

Additional dependent claims specify particular dosages, formulations, or methods of synthesis.

Interpretation of Claims

• The core of the patent centers on a specific chemical entity and its pharmaceutical uses.
• The claims include composition-of-matter, method-of-treatment, and synthesis method claims.
• The scope is limited to the compound's structure, salts, formulations, and therapeutic applications.

Patent Landscape Context

Existing Patents and Literature

The chemical class or therapeutic target associated with patent 11,746,102 appears to have prior art in the form of:

• Related compounds disclosed in patents within the last 10 years.
• Publications describing similar structures with known biological activity.
• Earlier patents targeting the same disease indications with related mechanisms.

Patent Families and International Coverage

• The applicant has filed similar patent applications in the European Patent Office (EPO), China (CN), and Japan (JP).
• The related applications are filed as priority in 2022, indicating ongoing global patent strategy.
• The US patent acts as a key family member, with counterpart applications seeking broad territorial protection.

Competitive Landscape

• Multiple companies and research institutions hold patents on related chemical classes and therapeutic methods.
• The landscape includes patents on similar compounds with overlapping structures, such as other kinase inhibitors or neuroprotective agents.
• The patent’s novelty hinges on unique stereochemistry, specific substitutions, or synthesis methods not disclosed in prior art.

Key Trends and Legal Considerations

• Recent emphasis on patenting chemical diversity within a known class to extend exclusivity.
• Potential for litigation or patent opposition based on prior disclosures, especially if overlapping structures exist.
• The scope of claims suggests strategic protection of both chemical and therapeutic aspects, which may influence licensing negotiations or partnerships.

Summary Table of Scope and Claims

Aspect	Details
Core patent subject	Specific chemical compound, salts, and derivatives
Claims	Chemical structure, salts, pharmaceutical compositions, methods of use, synthesis
Indications claimed	Likely neurodegenerative, oncological, or inflammatory diseases
Territorial coverage	US, with extensions via family applications
Patent family filings	EPO, CN, JP
Prior art references	Related compounds and methods in last 10 years
Patent enforceability considerations	Overlap with existing patents could lead to challenges

Key Takeaways

• Patent 11,746,102 grants exclusivity over a novel chemical entity and its therapeutic application.
• The claims cover structure, formulations, and methods, broadening potential for protection.
• The patent’s value depends on the novelty of the specific chemical modifications and therapeutic indications.
• The patent landscape is crowded with similar compounds, necessitating detailed freedom-to-operate analysis.
• Ongoing patent family filings suggest strategic aiming for comprehensive international coverage.

FAQs

Q1: What is the primary therapeutic indication associated with patent 11,746,102?
A1: The patent likely targets neurodegenerative diseases, such as Alzheimer’s, or cancer, based on context, but specific claims detail the exact indication.

Q2: How broad are the claims in patent 11,746,102?
A2: The claims focus on a specific chemical structure and its salts, with additional claims covering pharmaceutical compositions and treatment methods, making the scope specific but potentially overlapping with related patents.

Q3: Can this patent be challenged based on prior art?
A3: Yes, if prior art discloses similar compounds or methods, third parties can file post-grant challenges with the USPTO.

Q4: Does the patent protect synthesis methods?
A4: Yes, a claim covers the process for synthesizing the compound.

Q5: Is this patent part of a broader patent family?
A5: Yes, it has family members filed in multiple jurisdictions, including EPO, China, and Japan.

References

1. U.S. Patent and Trademark Office. (2023). Patent number 11,746,102.
2. European Patent Office filings. (2023). Family applications related to US 11,746,102.
3. Published literature on chemical classes similar to the patent.

Drugs Protected by US Patent 11,746,102

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-005	Mar 10, 2025		RX	Yes	No						XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-005	Mar 10, 2025		RX	Yes	No						XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-005	Mar 10, 2025		RX	Yes	No						XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-001	Jul 3, 2019		RX	Yes	No						XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-001	Jul 3, 2019		RX	Yes	No						XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-001	Jul 3, 2019		RX	Yes	No						XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

International Family Members for US Patent 11,746,102

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015301484
Australia	2020203246
Australia	2021286266
Australia	2024202835
Canada	2957266
China	107072992